---

---

sector : Health technology    symbols : TAK   

save search

---

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| Email alert Add to watchlist
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| Email alert Add to watchlist
MIRM | $23.6 -1.05% -1.06% 400K |

Health Technology

| Email alert Add to watchlist
report million reach treatment market

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -2.38% | O: -1.19% H: 0.26% C: -0.98%
company

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

---

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -9.68% | O: -0.07% H: 0.0% C: -0.96%
CNTG | $0.461 -3.96% -4.12% 23K |

Commercial Services

| -31.41% | O: 1.43% H: 1.41% C: -1.41%
partnership genetic takeda disorders

---

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.3% | O: 0.21% H: 0.97% C: 0.7%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -5.15% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -9.85% | O: -1.58% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -1.31% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -8.4% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -6.03% | O: -0.02% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K |

Health Technology

| -6.03% | O: -0.27% H: 1.26% C: 0.84%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -2.43% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

---

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.49% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

---

Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -9.68% | O: -0.69% H: 0.35% C: 0.14%
ARE A | $116.51 0.05% -0.01% 1.1M |

Finance

| -5.86% | O: -0.01% H: 1.98% C: 1.41%
extension

---

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -11.21% | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga

---

Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| -5.99% | O: -0.38% H: 0.14% C: -0.14%
KMDA | $5.075 -0.1% -0.1% 6.5K |

Health Technology

| -15.22% | O: 2.0% H: 2.28% C: 1.63%
ADMA 4 | $6.21 2.82% 2.74% 3M |

Health Technology

| 19.69% | O: 0.19% H: 2.5% C: 1.35%
report reach global set therapy growth market

---

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K |

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -5.13% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -6.33% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -3.44% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -6.54% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

---

Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Published: 2024-02-21 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -11.27% | O: -0.88% H: 0.34% C: 0.34%
entyvio disease biosimilar

---

Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research
Published: 2024-02-15 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K |

Communications

| -1.65% | O: 3.61% H: 0.0% C: -0.13%
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| -2.79% | O: -0.18% H: 1.09% C: 0.24%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -9.56% | O: -0.83% H: 0.38% C: 0.0%
reach research market

---

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
LZAGF | $579.0 -19.1% 49 |

Health Technology

| 12.7% | O: 3.14% H: 1.92% C: 1.92%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -3.81% | O: -2.14% H: 0.0% C: -0.63%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -0.29% | O: -2.71% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 9.56% | O: 0.87% H: 0.21% C: -2.23%
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| 15.41% | O: 4.07% H: 1.53% C: 1.45%
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| -1.04% | O: 0.56% H: 1.3% C: 1.22%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.3% | O: 0.42% H: 1.04% C: 0.97%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -8.08% | O: -0.91% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -4.32% | O: 0.89% H: 0.41% C: 0.1%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 1.05% | O: 0.38% H: 2.44% C: 1.54%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| 0.2% | O: 0.33% H: 0.63% C: -0.28%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -5.33% | O: -0.73% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| -5.49% | O: -0.83% H: 0.66% C: 0.38%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -1.43% | O: -1.1% H: 0.0% C: 0.0%
GLPG | $28.9 -1.1% -1.11% 140K |

Health Technology

| -25.19% | O: -1.72% H: 1.8% C: 1.59%
BIIB | $190.55 -0.84% -0.84% 1.5M |

Health Technology

| -13.9% | O: 0.16% H: 0.43% C: -2.76%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 11.85% | O: 0.28% H: 0.93% C: 0.75%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -8.79% | O: -0.21% H: 0.34% C: 0.07%
report global protein growth market

---

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.98 -0.47% -0.47% 470K |

Health Technology

| -7.02% | O: -3.56% H: 2.91% C: -3.34%
MOR | $18.02 -0.11% -0.11% 590K |

Health Technology

| 4.15% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $16.08 -0.12% -0.12% 590K |

Health Technology

| -10.16% | O: -5.25% H: 2.94% C: 2.18%
INCY | $52.82 0.19% 0.19% 1.8M |

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
financial

---

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -1.6% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 12.13% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -13.68% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -8.11% | O: 0.14% H: 0.35% C: 0.07%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -7.41% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -7.44% | O: 0.7% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -3.58% | O: 1.22% H: 0.07% C: -0.43%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 1.83% | O: -0.96% H: 1.75% C: 1.75%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -2.91% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -4.57% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | News | $14.2 3.5% 3.38% 690K |

Health Technology

| -25.59% | O: -1.15% H: 1.03% C: -1.5%
VRTX | News | $393.51 0.1% 0.1% 950K |

Health Technology

| -5.63% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -1.49% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.4 -0.42% -0.42% 11K |

Health Technology

| -8.91% | O: -3.1% H: 1.2% C: -0.8%
INCY | $52.82 0.19% 0.19% 1.8M |

Health Technology

| -8.68% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $190.55 -0.84% -0.84% 1.5M |

Health Technology

| -20.26% | O: -3.72% H: 0.58% C: -3.82%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 11.16% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $358.65 -2.06% -2.11% 240K |

Health Technology

| -5.61% | O: -2.3% H: 1.65% C: 0.83%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -10.02% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

---

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -7.65% | O: 0.07% H: 0.46% C: 0.42%
fda first treatment

---

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NBIX M | $132.49 -0.56% -0.56% 550K |

Health Technology

| -6.81% | O: -5.57% H: 6.04% C: 0.96%
financial results

---

Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K |

Health Technology

| -13.72% | O: -1.53% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 1.09% | O: -0.37% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -8.98% | O: 0.41% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K |

Manufacturing

| 37.02% | O: 1.71% H: 1.28% C: 0.94%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -14.23% | O: 0.28% H: 0.18% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -7.13% | O: 0.07% H: 0.42% C: 0.07%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -10.28% | O: 0.09% H: 0.39% C: -0.36%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -6.93% | O: 1.47% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 6.49% | O: 0.76% H: 4.31% C: 2.11%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -1.95% | O: -0.14% H: 0.35% C: -1.12%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -3.43% | O: 1.48% H: 0.0% C: 0.0%
VRTX | News | $393.51 0.1% 0.1% 950K |

Health Technology

| -5.09% | O: 0.15% H: 2.4% C: 0.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -2.19% | O: 1.33% H: 0.0% C: 0.0%
JAZZ | $109.3 2.05% 2.01% 560K |

Health Technology

| -14.12% | O: -0.02% H: 0.0% C: -1.4%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 1.83% | O: -0.4% H: 0.19% C: -0.33%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -16.18% | O: -0.18% H: 0.0% C: -6.22%
report cancer blood growth market

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---